CytomX Therapeutics Inc (NASDAQ:CTMX) – Research analysts at Jefferies Financial Group issued their Q3 2018 earnings per share (EPS) estimates for CytomX Therapeutics in a report issued on Wednesday, August 8th. Jefferies Financial Group analyst B. Amin anticipates that the biotechnology company will post earnings of ($0.57) per share for the quarter. Jefferies Financial Group also issued estimates for CytomX Therapeutics’ Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($1.98) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($3.12) EPS, FY2021 earnings at ($3.27) EPS and FY2022 earnings at ($3.33) EPS.
CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). CytomX Therapeutics had a negative net margin of 44.46% and a negative return on equity of 74.84%. The business had revenue of $21.34 million during the quarter, compared to the consensus estimate of $16.48 million.
Shares of CTMX stock opened at $22.56 on Monday. CytomX Therapeutics has a 52-week low of $13.51 and a 52-week high of $35.00. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -19.45 and a beta of 1.04.
In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 2,028 shares of the stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $25.09, for a total value of $50,882.52. Following the sale, the chief executive officer now directly owns 84,091 shares in the company, valued at $2,109,843.19. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $26.05, for a total transaction of $78,150.00. Following the sale, the chief financial officer now owns 8,638 shares in the company, valued at $225,019.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,577 shares of company stock worth $692,875. Company insiders own 8.50% of the company’s stock.
Several large investors have recently modified their holdings of the stock. FMR LLC raised its holdings in shares of CytomX Therapeutics by 0.9% during the second quarter. FMR LLC now owns 5,843,626 shares of the biotechnology company’s stock worth $133,586,000 after acquiring an additional 51,953 shares during the period. BlackRock Inc. raised its holdings in shares of CytomX Therapeutics by 28.5% during the second quarter. BlackRock Inc. now owns 3,226,401 shares of the biotechnology company’s stock worth $73,755,000 after acquiring an additional 716,096 shares during the period. Renaissance Technologies LLC raised its holdings in shares of CytomX Therapeutics by 46.8% during the second quarter. Renaissance Technologies LLC now owns 1,411,500 shares of the biotechnology company’s stock worth $32,267,000 after acquiring an additional 450,300 shares during the period. Aquilo Capital Management LLC acquired a new stake in shares of CytomX Therapeutics during the second quarter worth $14,853,000. Finally, FIL Ltd raised its holdings in shares of CytomX Therapeutics by 36.5% during the first quarter. FIL Ltd now owns 429,925 shares of the biotechnology company’s stock worth $12,231,000 after acquiring an additional 114,962 shares during the period. Institutional investors and hedge funds own 76.48% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Article: Trading Strategy Methods for Individual Investors
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.